Advertisement
Singapore markets close in 38 minutes
  • Straits Times Index

    3,267.99
    +42.82 (+1.33%)
     
  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     
  • Hang Seng

    16,823.04
    +311.35 (+1.89%)
     
  • FTSE 100

    8,053.69
    +29.82 (+0.37%)
     
  • Bitcoin USD

    66,115.73
    -21.66 (-0.03%)
     
  • CMC Crypto 200

    1,393.86
    -20.90 (-1.48%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • Dow

    38,239.98
    +253.58 (+0.67%)
     
  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     
  • Gold

    2,321.30
    -25.10 (-1.07%)
     
  • Crude Oil

    82.71
    +0.81 (+0.99%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • FTSE Bursa Malaysia

    1,561.83
    +2.24 (+0.14%)
     
  • Jakarta Composite Index

    7,117.45
    +43.63 (+0.62%)
     
  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

How Neurocrine Biosciences Performed in the Second Quarter

How Neurocrine Biosciences Performed in the Second Quarter

Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.